I. Introduction
The purine nucleoside adenosine has been identified as a major local tissue function regulator, particularly when cellular energy supply fails to meet the demand. Given its ability to equalize energy intake to metabolic demand, in the 1980s it was reputed to be a "retaliatory metabolite" Fredholm, 2014) . Adenosine is omnipresent, it is released by nearly all cells and is generated in the extracellular space through ATP breakdown by a series of ectoenzymes, including apyrase (CD39) and 59-nucleotidase (CD73) (Zimmermann, 2000) . The latter dephosphorylates extracellular AMP to adenosine, thus regulating the step that limits its formation. Extracellularly, adenosine concentration equilibrium is maintained by reuptake mechanisms operated through the action of specific transporters. Then, inside the cell, it is phosphorylated to AMP by adenosine kinase or degraded to inosine by adenosine deaminase. Intracellularly, adenosine formation is dependent upon the hydrolysis of AMP by an intracellular 5-nucleotidase or by hydrolysis of S-adenosyl-homocysteine. It is estimated that the levels of adenosine in the interstitial fluid fall within the 30-300 nM range (Fredholm et al., 2001) .
Adenosine concentrations increase under metabolically unfavorable conditions. Tissue hypoxia, for example, leads to enhanced breakdown of ATP and increased generation of adenosine. In addition to this route, the release of adenosine might be potentiated by hypoxiadependent inhibition of the salvage enzyme, adenosine kinase, which rephosphorylates the nucleoside to AMP (Decking et al., 1997) . As adenosine is unstable, its half-life limited by deamination or cellular reuptake, a hypoxiainduced increase typically affects only local adenosine receptor signaling. Adenosine most likely belongs to the group of autacoids because it is not released in a transmitter or hormone-like fashion.
Adenosine mediates its effects by activation of a family of four G protein-coupled receptors (GPCRs): the A 1 , A 2A , A 2B , and A 3 adenosine receptors (ARs) (Ralevic and Burnstock, 1998) . These receptors differ in 1) their affinity for adenosine, 2) the type of G proteins they recruit and, finally, 3) the downstream signaling pathways activated in the target cells. A 1 and A 3 ARs inhibit the regulation of adenylyl cyclase (AC) activity, whereas activation of the A 2A and A 2B AR subtypes stimulates AC, which leads to increases in cAMP levels. Early pharmacologic evidence for the existence of ARs was provided by specific antagonism-exerted by methylxanthines, caffeine, and theophylline-of adenosine-induced effects in the heart and brain (Sattin and Rall, 1970) .
ARs are widely distributed throughout the body and the fact they are present in basically all cells makes them an interesting target for pharmacologic intervention in many pathophysiologic conditions linked to increased adenosine levels. Development of AR agonists/antagonists would, therefore, seem opportune, but the challenge is to ensure they are devoid of side effects.
In particular, A 3 AR is now recognized as a potential therapeutic target and biologic marker given its overexpression in inflammatory and cancer cells, compared with low levels found in healthy cells. Fortunately, recent developments in the field of AR agonists and antagonists have helped scientists design and develop safer, more specific lead and back-up candidates for clinical development (Gessi et al., 2011a) . The agonists are now considered protective agents in some therapeutic areas and drug candidates in both preclinical and clinical studies. The goal of this review is to cover both the basic science and relevant therapeutic applications of A 3 AR ligands and provide an authoritative account of the current status of the field.
II. The Discovery of the A 3 Adenosine Receptor
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The A 3 Receptor: History and Perspectives 75 neuromuscular junction (Ribeiro and Sebastião, 1984) . A distinct AR was claimed to exist in the brain that was coupled to Ca 2+ metabolism (Ribeiro and Sebastião, 1986 ). However, this was not the same A 3 AR finally cloned. Another milestone on the way to the definition of the A 3 AR was found in antigen-stimulated RBL-2H3 cells (Ali et al., 1990) . This receptor was not given a name, but subsequent work identified it as what we now know as the A 3 AR. Therefore the receptor functionally coupled, via a G protein, to phospholipase C (PLC) and Ca 2+ in a stimulatory manner was distinguished from the putative A 3 AR, which inhibited Ca 2+ -dependent responses in electrically excitable tissues independently of AC (Ribeiro and Sebastião, 1986) .
Then, isolation of a cDNA clone encoding a novel putative GPCR from a rat testis cDNA library was reported. Although the ligand for this receptor was not identified, the authors understandably speculated that the receptor, designated tgpcr1, could play a role in male reproduction (Meyerhof et al., 1991) . In 1992, several cDNA sequences from rat striatum encoding GPCRs were reported, one of which (designated R226) was identical to tgpcr1 (Zhou et al., 1992) . On the basis of the transmembrane domain sequence homology with adenosine A 1 (58%) and A 2A ARs (57%) and its particular ability to bind AR ligands, it was concluded that R226 encoded a novel AR designated as A 3 AR (Fozard, 2010) . The high expression of the receptor in the testis was confirmed, but, more importantly, low level mRNAs were also shown to be present in the lungs, kidneys, heart, and parts of the central nervous system (CNS), implying that A 3 AR could have more widespread biologic significance than simply modulating testicular function. Therefore, A 3 AR is the only AR subtype to be cloned before its pharmacologic identification.
III. Molecular Characterization of the A 3 Adenosine Receptor
Homologs of the rat striatal A 3 AR have been cloned from sheep and humans, thus revealing large interspecies differences in A 3 AR structure. For example, rat A 3 AR presents only a 74% sequence homology with sheep and human A 3 AR, whereas between sheep and humans, this homology is 85%; moreover equine A 3 AR has also shown a high degree of sequence similarity with that of humans and sheep (Brandon et al., 2006) . This is reflected in the very different pharmacologic profiles of the species homologs, especially in terms of antagonist binding, which has made characterization of this AR subtype difficult.
A 3 AR has been mapped on human chromosome 1p21-p13 (Atkinson et al., 1997) and consists of 318 amino acid residues. It has been determined that the A 3 AR gene contains two exons separated by a single intron of about 2.2 kb (Murrison et al., 1996) . The upstream sequence does not contain a TATA-like motif, but it does have a CCAAT sequence and consensus binding sites for SP1, NF-IL6, GATA1, and GATA3 transcription factors. Involvement of the latter in transcriptional control of this gene would be consistent with the receptor playing a role in immune function.
A 3 AR is a GPCR characterized by its C-terminal portion, which faces the intracellular compartment and seven transmembrane spanning domains. This region presents multiple Ser and Thr residues that may serve as potential phosphorylation sites of importance for rapid receptor desensitization upon agonist application (Palmer and Stiles, 2000) . Phosphorylation leads to a decreased number of receptors in the high-affinity state and decreased agonist potency to inhibit AC activity. In human astrocytoma and murine melanoma cells, a short agonist exposure time results in rapid A 3 AR internalization and functional desensitization, whereas prolonged treatment with the A 3 AR agonists induces receptor uncoupling with receptor downregulation (Trincavelli et al., 2002a; Madi et al., 2003) . This event was suggested to be mediated by mitogen-activated protein kinases (MAPKs) responsible for a feedback mechanism that controls GPCR kinase activity and receptor phosphorylation in Chinese hamster ovary (CHO) cells transfected with A 3 AR (Trincavelli et al., 2002b ). An A 3 AR desensitization mechanism has also been proposed in rat hippocampal slices during oxygen and glucose deprivation (Pugliese et al., 2007) .
To gain an insight into the molecular characteristics of A 3 AR ligand interaction, a thermodynamic analysis of A 3 AR binding site has been addressed. This original approach has shown that agonist binding is always totally entropy driven, whereas antagonist binding is driven by both enthalpy and entropy (Merighi et al., 2002b) . Interestingly, the similarity between the thermodynamic parameters of all ARs most likely reflects a common ligand receptor interaction mechanism for ARs . This may explain the difficulty in obtaining selective adenosine ligands. Therefore, the availability of thermodynamic data adds important information to the decision-making process in drug development (Gessi et al., 2008a) .
IV. Medicinal Chemistry and Pharmacology of A 3
Adenosine Receptor Ligands
A. Agonists
Potent and selective A 3 AR agonists stem from multiple substitutions of the parent nucleoside, adenosine (Fig. 1) . The structural modifications implicate N 6 -, C 2 -, and 59-substitutions combined with the modification of ribose moiety.
Prototypical A 3 AR agonists, such as N 6 -(3-iodobenzyl) adenosine-59-N-methyluronamide (IB-MECA, CF101), derive from a combined modification of adenosine at the 59-and at N 6 -positions ( Fig. 1 ) . In receptor binding studies, IB-MECA has 76 displayed constant inhibitory binding (K i ) values of 51, 2900, and 1.8 nM for human (h) A 1 , A 2A , and A 3 ARs, respectively, being 28-and 1611-fold selective against A 1 and A 2A ARs (Table 1 ). The introduction of small groups at the C2 position of IB-MECA generally increased both A 3 AR affinity and selectivity, thus leading to the discovery of 2-chloro-N 6 -(3-iodobenzyl)-adenosine-59-Nmethyluronamide (Cl-IB-MECA, CF102), a potent A 3 AR agonist with a K i value of 1.4 nM at hA 3 AR and with good selectivity for the other ARs ( Fig. 1 ; Table 1 ) (Kim et al., 1994) . On the basis of the bioisosteric rationale, the 49-thio analogs of Cl-IB-MECA were synthesized as A 3 AR ligands (Jeong et al., 2003) . Among them, 2-chloro-N 6 -(3-iodobenzyl)-5-N-methylcarbamoyl-4-thioadenosine (LJ529) displayed a K i value of 0.38 nM at the hA 3 AR (Fig. 1) . LJ529 is reported to have a higher binding affinity to hA 3 AR than Cl-IB-MECA (K i = 0.38 versus 1.4 nM; Table 1 ) (Jeong et al., 2003) .
Another class of analogs structurally related to the adenosine core consists of derivatives having 2-(ar)-alkynyl chains combined with various substituents at the 6-position. In particular, 2-phenylethynyl-N 6 -methyladenosine (PEMADO) has shown hA 3 AR affinity in the low nanomolar range (K i = 0.44 nM), with A 1 /A 3 and A 2A /A 3 selectivity of about 74,000 and 94,000, respectively ( Fig. 1 ; Table 1 ) (Volpini et al., 2002) . The ability to inhibit forskolin-stimulated AC has been tested and all these derivatives have proved to be partial A 3 AR agonists; their efficacy is not significantly modified by the introduction of small alkyl substituents in the N 6 -position (Volpini et al., 2009) . One compound in this series, 2-hexyn-1-yl-N 6 -methyladenosine (HEMADO), has shown high affinity (K i = 1.1 nM) and 300-and 1091-fold selectivity versus the A 1 and A 2A AR subtypes, respectively ( Fig. 1 ; Table 1 ). The tritium-labeled form [ 3 H]HEMADO binds to hA 3 AR with an affinity equilibrium binding constant (K D ) of 1.1 nM (Klotz et al., 2007) . Efforts to identify A 3 AR agonists that are both potent and selective have led to the discovery of 39-amino analogs properly modified at the 59-and N 6 -positions. One of these, N 6 -[2-(3-methylisoxazol-5-ylmethoxy)-5-chloro]benzyl-39-amino-adenosine-59-N-methylcarboxamide, coded CP608,039, binds to hA 3 AR with a K i of 5.8 nM and possesses over 1000-and 8000-fold selectivity versus hA 1 and hA 2A AR, respectively ( Fig. 1 ; Table 1 ). Compound CP608,039 displays full agonist activity at The A 3 Receptor: History and Perspectives 77 the hA 3 AR, inhibiting the isoproterenol-stimulated cAMP increase with an EC 50 of 3.4 nM (DeNinno et al., 2003) .
Other selective A 3 AR agonists have been reported based on modification of the ribose ring. The analogs contain the (N)-methanocarba (bicyclo[3.1.0]hexane) ring system, a rigid ribose substitute lacking the ether oxygen (Tchilibon et al., 2005) . In this series, 4-[6-(3-chlorobenzylamino)-2-chloro-9H-purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (MRS3558, CF502) has the pharmacologic profile of a full agonist with subnanomolar affinity (K i = 0.29 nM for the hA 3 AR; Table 1) (Fig. 1) . This compound shows an 897-fold selectivity versus the hA 1 AR subtype, whereas it is greatly reduced (11-fold) in the mouse due to an increased tolerance of this ring system at A 1 AR. As in the 2-alkynyl (N)-methanocarba derivative (MRS5151), the introduction of 2-alkynyl chains of varying lengths tends to increase A 3 AR selectivity in the mouse (m) (up to 430-fold) and preserve it in humans (6261-fold) ( Fig. 1 ; Table 1 ). Molecular modeling predicted that the sulfonate groups on C2-phenylethynyl substituents would provide high affinity at both m/hA 3 AR, whereas a N 6 -psulfophenylethyl substituent would determine higher hA 3 AR versus mA 3 AR affinity. N 6 -3-Chlorobenzyl-2-(3-sulfophenylethynyl) derivative (MRS5841) binds selectively to human and mouse A 3 ARs (K i hA 3 AR = 1.9 nM) as an agonist, whereas the corresponding p-sulfo isomer (MRS5701) displays mixed A 1 /A 3 AR agonism (Paoletta et al., 2013) .
In this context, different chemically functionalized alkynyl chains (esters, amino groups, or carboxylic acid) potentially useful for making conjugates as receptor probes have been synthesized (Melman et al., 2008) . Recently, macromolecular conjugates [e.g., polyamidoamine (PAMAM) dendrimers], a particularly versatile and biocompatible class of polymeric drug carriers of chemically functionalized agonists, have been synthesized as potent polyvalent activators of A 3 AR (Tosh et al., 2010) .
B. Antagonists
In an initial attempt, a large number of heterocyclic compounds were synthesized and evaluated as A 3 AR antagonists Siddiqi et al., 1995; Ji et al., 1996) . In particular a triazoloquinazoline derivative 9-chloro-2-(2-furanyl)-5- [(phenylacetyl) (Kim et al., 1996) .
Several xanthine or purine analogs were examined first, but none showed significant affinity or selectivity to rat (r) A 3 AR ).
An approach to designing dihydropyridines that bind to ARs without binding to L-type calcium channels has been described. For example, a trisubstituted 1,4-dihydro-6-phenylpyridine analog 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (MRS1191), has been found to inhibit radioligand binding at the hA 3 AR with a K i value of 31.4 nM ( Fig. 2 ; Table 2 ), whereas the same derivative is nearly inactive in binding at A 1 and A 2A ARs . One of the first heterocyclic, selective, and competitive A 3 AR antagonists was 3-propyl-6-ethyl-5[(ethylthio) carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate (MRS1523), a pyridine derivative that acts as a highly selective antagonist of A 3 AR with good potency in both humans and rodents, with K i values of 18.9 nM for hA 3 AR and 113 nM for rA 3 AR ( Fig. 2 ; Table 2 ) (Li et al., 1998) . MRS1523 exhibits only a weaker antagonistic activity toward A 1 and A 2A ARs (K i = 15.6 and 2.05 mM for rA 1 and A 2A ARs, respectively) (Li et al., 1998) .
Another class of analogs, structurally related to isoquinoline and quinazoline urea derivatives, was found as adenosine A 3 AR antagonists. The combination of the optimal substituents in the two series led to the potent hA 3 AR antagonist N-(2-methoxyphenyl)-N9-(2-(3-pyridyl)quinazolin-4-yl)urea VUF-5574, with a K i value of 4.03 nM and over 2400-fold selectivity versus A 1 Table 2 ). In an in vitro functional assay, the compound competitively antagonized the inhibition of cAMP production induced by N 6 -ethylcarboxamidoadenosine in CHO cells expressing hA 3 AR with a pA 2 value of 8.1 (van Muijlwijk-Koezen et al., 2000) .
The first example of an AR antagonist containing the pyrazolo-triazolo-pyrimidine scaffold was reported in 1993 (Gatta et al., 1993) . Intensive efforts in the chemical synthesis of compounds based on the systematic substitution at the C 2 -, C 5 -, C 9 -, N-7 , and N 8 -positions of the tricyclic template led to the MRE series (Baraldi et al., 1999 . Table 2 ) and high selectivity (1463-and 172-fold) over human A 1 and A 2A ARs, respectively ( Fig. 2) . In a functional assay MRE 3008F20 showed antagonist activity capable of blocking the effect of IB-MECA on cAMP production in CHO cells (IC 50 = 4.5 nM). The tritium-labeled compound was able to bind the hA 3 AR expressed in CHO cells with a K D value of 0.82 nM and a B max value of 297 fmol/mg protein . The isosteric replacement of the phenyl with a 4-pyridyl moiety led to the water-soluble hA 3 (Fig. 2) . In receptor binding assays, OT-7999 displayed high affinity for the hA 3 AR (K i = 0.95 nM) and .10,526-fold selectivity relative to other AR subtypes ( Table 2 ). The ring annelation of xanthine derivatives for the development of AR antagonists has been investigated in depth (Okamura et al., 2002) . The pyrido[2,1-f]purine-2,4-diones, which could be considered tricyclic xanthine derivatives, have been reported to exert subnanomolar affinity to hA 3 AR (Drabczy nska et al., 2003) . An important innovation of such a series, compared with xanthines, is the significant increase in water solubility, achieved by introducing a basic nitrogen atom, which could be protonated under physiologic conditions.
The imidazopurinone ring-enlarged 8(R)-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one (PSB-10) has shown high affinity for hA 3 ARs (K i = 0.44 nM) with high selectivity over A 1 and A 2A ARs (3864-and 6136-fold, respectively; Fig. 2 ; Table 2 ) (Muller et al., 2002) . PSB-10 has demonstrated inverse agonist activity in binding studies in CHO cells expressing recombinant hA 3 AR (IC 50 = 4 nM). Another similar compound of this series is 8(R)-ethyl-7,8-dihydro-4-methyl-2-phenyl-1H-imidazo[1,2-g] purin-5-one (PSB-11), exhibiting a K i value of 2.34 nM for the hA 3 AR and good selectivity versus all other AR subtypes (Ozola et al., 2003) (Fig. 2 ; Table 2 ). concentrations in human promyelocytic cells (Saki et al., 2002) .
Interestingly, the 5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate compound was presented as a ligand with high affinity, able to serve as the first positron emission tomography tracer for the A 3 AR (Wadsak et al., 2008) .
Moreover, a very recent study has obtained a novel series of A 3 AR partial agonists and antagonists as truncated 2-hexynyl-N 6 -substituted-(N)-methanocarba nucleosides, with K i values of 7.8216.0 nM (Nayak et al., 2014) . These compounds were screened for renoprotective effects in a human kidney fibrosis model. Most compounds exhibited antifibrotic effects, with (1R,2R,3S,4R,5S)-4-(2-(hex-1-ynyl)-6-(methylamino)-9H-purin-9-bicyclo[3.1.0]hexane-2,3-diol (Structure A) being the most potent, indicating its potential as a good therapeutic candidate for treating renal fibrosis ( Fig. 2 ; Table 2 ).
V. Distribution of the A 3 Adenosine Receptor
The generation of cDNA for A 3 AR has made the identification of the tissue distribution of this receptor subtype possible. A 3 AR is widely expressed, its mRNA being revealed in the testis, lung, kidneys, placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon, and eye of rats, sheep, and humans (Zhou et al., 1992; Salvatore et al., 1993; Linden, 1994;  Rivkees, 1994; Dixon et al., 1996; Burnett et al., 2010) . However, marked differences in expression levels do exist within and between species. In particular, rat testis and mast cells express high concentrations of A 3 mRNA, whereas low levels have been detected in most other rat tissues Salvatore et al., 1993) . Human lung and liver are the organs that express high amounts of A 3 mRNA, whereas levels in the aorta and brain have been found to be low (Salvatore et al., 1993) . The lung, spleen, pars tuberalis, and pineal gland express the highest concentrations of A 3 mRNA in sheep.
The presence of the A 3 AR protein has been evaluated through radioligand binding, immuno-or functional assays in a variety of primary cells, tissues (Table 3) , and cell lines (Table 4 ). In the brains of mouse, rat, gerbil, and rabbit, a widespread, relatively low level of A 3 AR binding sites has been found Ji et al., 1994) . Owing to this very low expression, other authors have reported the impossibility of detecting either the A 3 AR gene or binding site in the CNS from in situ hybridization experiments (Rivkees et al., 2000) , and others have described A 3 AR expression in the thalamus and hypothalamus (Yaar et al., 2002) . However, electrophysiologic and biochemical evidence suggests the presence of A 3 AR in the rat hippocampus (Dunwiddie et al., 1997; Macek et al., 1998; Lopes et al., 2003) and cortex (Brand et al., 2001) ; functional studies have also indicated its presence in the brain and retinal ganglion cells von Lubitz et al., 1994; Haskó et al., 2005; Zhang et al., 2006a Zhang et al., , 2010 . The proposed presence of A 3 AR at motor nerve terminals (Ribeiro and Sebastião 1986) was recently demonstrated through pharmacologic and immunohistochemical studies (Cinalli et al., 2013) . At cellular level, A 3 AR expression has been observed in microglia and astrocytes, the resident immune cells of the CNS (Hammarberg et al., 2003; Björklund et al., 2008a,b; van der Putten et al., 2009; Ohsawa et al., 2012; Gessi et al., 2013) . Overall these data iron out the controversy as to whether A 3 AR are in fact in the CNS.
In cardiomyocytes no direct evidence of the presence of A 3 AR has been found (Peart and Headrick, 2007) ; however, a plethora of studies has reported it as being responsible for cardioprotection in a variety of species and models, including isolated cardiomyocytes and isolated myocardial muscle preparations (Tracey et al., 1997; Shneyvays et al., 1998 Shneyvays et al., , 2001 Thourani et al., 1999a,b; Cross et al., 2002; Harrison et al., 2002; Headrick and Peart, 2005; Xu et al., 2006) . High A 3 AR expression has been revealed in the human coronary and carotid artery (Hinze et al., 2012; Grandoch et al., 2013) .
In enteric neurons and epithelial cells, the A 3 AR was first evidenced by immunohistochemical studies (Christofi et al., 2001; Antonioli et al., 2010; Ren et al., 2011) and subsequently quantified in colonic mucosa by radioligand binding experiments (Gessi et al., 2004a) . The presence of functional A 3 AR has also been demonstrated in human lung parenchyma, in lung type 2 alveolar-like cells (A549), and in bronchi through radioligand binding and immunohistochemical assays Calzetta et al., 2011) .
It is worth noting that A 3 AR has been revealed in a variety of primary cells involved in inflammatory responses. In rat basophilic leukemia cells (RBL-2H3), binding experiments have detected a high A 3 AR density (Ramkumar et al., 1993; Olah et al., 1994) and different studies have reported that A 3 AR plays a role in rat mast cell degranulation Fozard and Carruthers, 1993; Ramkumar et al., 1993; Hannon et al., 1995; el-Hashim et al., 1996; Fozard et al., 1996; Hua et al., 2008; Gomez et al., 2011) . Recently, A 3 AR stimulating degranulation has been demonstrated also in LAD2 bone marrow-derived human mast cells (Leung et al., 2014) . Human eosinophils were the first cells in which native hA 3 AR was detected by using radioligand binding (Kohno et al., 1996a; Morschl et al., 2008) , and this was then followed by human neutrophils (Bouma et al., 1997; Gessi et al., 2002; Chen et al., 2006; van der Hoeven et al., 2008; Corriden et al., 2013; Mulloy et al., 2013) , monocytes (Broussas et al., 1999 (Broussas et al., , 2002 Thiele et al., 2004) , macrophages (McWhinney et al., 1996; Szabo et al., 1998; Gessi et al., 2010a) , foam cells (Gessi et al., 2010a) , dendritic cells (Panther et al., 2001; Fossetta et al., 2003; Dickenson et al., 2003; Hofer et al., 2003) , lymphocytes (Gessi et al., 2004b; Varani et al., 2009 Varani et al., , 2010b , splenocytes, bone marrow cells, lymphonodes , and synoviocytes (Varani et al., 2008 (Varani et al., , 2010c Stamp et al., 2012) . Human chondrocytes and osteoblasts, two key cell types in the skeletal system, were recently found to express A 3 AR .
Finally, very high A 3 AR protein expression was observed in a variety of cancer cell lines (Gessi et al., , 2007 Merighi et al., 2001 Merighi et al., , 2009 Suh et al., 2001; Morello et al., 2009; Jajoo et al., 2009; Cohen et al., 2011; Hofer et al., 2011; Varani et al., 2011a Varani et al., , 2013 Kanno et al., 2012; Nogi et al., 2012; Kamiya et al., 2012; Otsuki et al., 2012; Vincenzi et al., 2012; Nagaya et al., 2013; Sakowicz-Burkiewicz et al., 2013; Madi et al., 2013) and in cancer tissues (Gessi et al., 2004a; Madi et al., 2004; Bar-Yehuda et al., 2008; Varani et al., 2011a) , thus suggesting a role for this subtype as a tumoral marker.
VI. Intracellular Pathways Regulated by the A 3
Adenosine Receptor (Fig. 3) . In transfected CHO cells, the ability of both recombinant hA 3 ARs to inhibit cAMP accumulation and endogenous A 3 ARs in RBL-2H3 to stimulate PLC is abolished by pretreatment with pertussis toxin, suggesting a functional coupling of this G i protein receptor (Ali et al., 1990; Zhou et al., 1992; Varani et al., 2000) . Furthermore, A 3 ARs signaling could increase phosphatidylinositol-specific PLC activity (Ali et al., 1990; Ramkumar et al., 1993; Abbracchio et al., 1995; Zheng et al., 2007) and cause the release of Ca 2+ from intracellular stores in different cellular models Merighi et al., 2001; Englert et al., 2002; Fossetta et al., 2003; Shneyvays et al., 2004 Shneyvays et al., , 2005 Kim et al., 2012) . In a broad study of site-directed mutagenesis of the A 3 AR, the mutation of the highly conserved tryptophan (W6.48) in the transmembrane domain 6 of GPCRs was first characterized . Recently, it was reported that this residue plays an important role in determining the structural basis of agonist efficacy and ligand bias in activating A 3 AR intracellular signaling (Stoddart et al., 2014) .
In addition to GPCR recruitment, it has been reported that A 3 AR stimulation activates other important pathways, such as the monomeric G protein RhoA and phospholipase D, thus inducing cardioprotection Mozzicato et al., 2004) . In cardiac cells, A 3 AR triggers sarcolemmal K ATP channels, mediating A 3 AR-dependent protection from ischemia/reperfusion (IR) injury (Tracey et al., 1998; Wan et al., 2008) . However, the opening of a mitochondrial K ATP channel has also been proposed as the end effector of the late preconditioning obtained through A 3 AR stimulation in mice (Zhao and Kukreja, 2002) . Considerable evidence supports the involvement of protein kinase C (PKC) in both early and delayed preconditioning (Liu et al., 1994) . In particular ischemic preconditioning-mediated cardioprotection has been achieved through A 2B /A 3 AR stimulation of PKCɛ-triggered aldehyde dehydrogenase type-2 activation in cardiac mast cells (Koda et al., 2010) . As for delayed preconditioning, PKCd has been shown to play an essential role in the cellular signaling cascade that produces the protective effect of A 3 AR stimulation in the mouse heart (Zhao and Kukreja, 2003) . Cl 2 channel activation by ischemic preconditioning and a nonselective A 1 /A 3 AR agonist has also been revealed as a mechanism inducing protection against ischemia/ reperfusion injury by enhancing cell volume regulation (Diaz et al., 2010) .
Moreover PLC, PKC, or chelation of intracellular Ca 2+ has been implicated in the reduction of excitotoxicity and in the increase of neuroprotection through the activation of metabotropic glutamate receptor 1 and A 3 AR (Dennis et al., 2011) . PKC is also involved in the stimulatory effect induced by Cl-IB-MECA on tumor necrosis factor a (TNF-a) release in lipopolysaccharide (LPS)-stimulated macrophages (Forte et al., 2011) . There is considerable evidence for A 3 AR-mediated effects on MAPKs in a multitude of different cellular models (Merighi et al., 2010) . The first example of A 3 AR-mediated activation of extracellular signalregulated kinases (ERK1/2) and the modulation of mitogenesis was described in human fetal astrocytes (Neary et al., 1998) . Subsequent and more detailed studies have been performed in CHO cells stably expressing A 3 AR (Schulte and Fredholm, 2000) . A 3 AR signaling to ERK1/2 in CHO cells proved to be dependent on bg release from pertussis toxin-sensitive G proteins, phosphoinositide 3-kinase (PI3K), Ras, and MAP kinase kinase (MEK) (Schulte and Fredholm, 2002) . Importantly, there are several examples of ERK1/2 phosphorylation mediated by endogenously expressed A 3 AR, e.g., in both primary mouse microglia cells and the N13 microglia cell line, in colon carcinoma, glioblastoma, and in foam cells (Hammarberg et al., 2003; Merighi et al., 2006 Merighi et al., , 2007a Gessi et al., 2010a, b) . In contrast, in melanoma cells, A 3 AR stimulation is unable to activate ERK phosphorylation, whereas A 3 AR antagonists are able to improve MEK activity (Fishman et al., 2002b; Merighi et al., 2002a) . Indeed, it was demonstrated that A 3 AR inhibits A375 melanoma cell proliferation by impairment of ERK activation, a discrepancy that may be due to the presence of different signaling pathways in different cell lines, possibly due to crosstalk between the PI3K/AKT and ERK1/2 pathways Upon activation of the A 3 AR by adenosine 1) the Ga subunit is dissociated from the receptor and Gbg and decreases AC catalytic activity and cAMP production; 2) PLC is activated leading to Ca 2+ increase or PI3K, Akt phosphorylation; 3) G protein RhoA and PLD are stimulated; 4) MAPK family, ERKs, JNK, p38, is modulated; and 5) K ATP channels are opened. The final targets downstream these pathways are a series of transcription factors, such as NF-kB, CREB, HIF-1a, c-myc. Thus, A 3 AR can elicit multiple signaling pathways within a cell. 84 (Merighi et al., 2005b) . In addition, in prostate cancer cells, A 3 AR inhibits ERK1/2 activity through the reduction of AC and protein kinase A (Jajoo et al., 2009) . In glioma, Cl-IB-MECA mediates suppression of ERK1/2, thus inducing caspase-dependent cell death (Kim et al., 2012) . Inhibition of ERK1/2 is also associated with the A 3 AR inhibition of LPS-stimulated TNF-a release in mouse RAW 264.7 cells (Martin et al., 2006) . Importantly, MAPK activation has been implicated in IR injury where ERK1/2 exerts a cytoprotective effect, whereas p38 and c-Jun amino-terminal kinase promote cell injury and death. It has been reported that pretreatment with A 3 AR agonists upregulates phosphorylated ERK1/2 levels, inducing a marked improvement in lung injury and attenuation of apoptosis after reperfusion (Matot et al., 2006) . Interestingly, A 3 AR activation in rat cardiomyocytes has proved to increase ERK1/2 phosphorylation by involving G i/o proteins, PKC, and Tyr kinase-dependent/independent pathways .
In addition to ERK1/2, there is experimental evidence that A 3 ARs also activate p38 MAPKs in several cellular models, e.g., hCHO-A 3 , hypoxic melanoma, glioblastoma, and colon carcinoma cells (Hammarberg et al., 2004; Merighi et al., 2005a Merighi et al., , 2006 Merighi et al., , 2007b . This pathway has also been observed in A 3 AR-stimulated activity of antidepressant-sensitive serotonin transporters (Zhu et al., 2011) . A 3 AR activation protects cardiomyocytes from hypoxia via phosphorylation of p38 MAPK, located downstream of the mitochondrial K ATP channel opening (Leshem-Lev et al., 2010) . Accordingly, increased phosphorylation of p38 has been found after Cl-IB-MECA treatment, which proves beneficial, protecting the rat heart subjected to ischemia (Hochhauser et al., 2007) . In contrast, activation of A 2A and A 3 ARs inhibits p38 MAPK and nuclear factor-kB (NF-kB) pathways in human synoviocytes (Varani et al., 2010c) . As for c-Jun amino-terminal kinase, activation by A 3 AR has been retrieved in microglia, leading to cell migration (Ohsawa et al., 2012) , and in glioblastoma cells, mediating an increase in matrix metalloproteinase-9 (MMP-9) .
Another relevant pathway associated with A 3 ARs is the PI3K/Akt . A 3 AR activation triggers phosphorylation of Akt, protecting rat basophilic leukemia 2H3 mast cells from apoptosis by signaling, which involves the bg subunits of G i and PI3K-b (Gao et al., 2001 ). Moreover, it was demonstrated that A 3 AR increases Akt phosphorylation in rat cardiomyocytes . Recently, transient catecholamine administration was found to trigger preconditioning via generation of adenosine and oxygen free radicals (ROS), thus activating the A 3 AR, PI3K/Akt and ERK in rat hearts and leading to cardioprotection (Salie et al., 2012) . In glioblastoma cells, activation of PI3K-Akt-pBad by A 3 AR stimulation was demonstrated to trigger inhibition of paclitaxel-induced apoptosis (Merighi et al., 2007a) . This pathway was also observed in cardiac myocytes subjected to ischemia/hypoxia and reperfusion/reoxygenation (Hussain et al., 2014) . In human melanoma A375 and glioblastoma cells, A 3 AR stimulation has produced PI3K-dependent phosphorylation of Akt with antiproliferative effect and MMP-9 increase, respectively (Merighi et al., 2005b; Gessi et al., 2010b) .
There is accumulating evidence that the antiinflammatory A 3 AR-mediated activity uses the PI3K/ Akt and NF-kB signaling pathways. In LPS-treated BV2 microglial cells and in monocytes, A 3 AR activation suppresses TNF-a and interleukin (IL)-12 production, respectively, by inhibiting PI3K/Akt and NF-kB activation (Hasko et al., 1998; la Sala et al., 2005; Lee et al., 2006a Lee et al., , 2011 . Inhibition of Akt is triggered by A 3 AR for the reduction of LPS-mediated hypoxiainducible-factor 1a (HIF-1a) accumulation in murine astrocytes . Downregulation of the PI3K/Akt-NF-kB signaling pathway has also been observed in the inhibitory effect of IB-MECA in adjuvantinduced arthritis and in mesothelioma Madi et al., 2007; Varani et al., 2011a) . Recently, it was reported that A 3 AR suppresses angiogenesis by inhibiting PI3K/Akt/mammalian target of rapamycin signaling in endothelial cells (Kim et al., 2013) . On the other hand, activation of the PI3K/Akt signaling pathway is triggered by A 3 AR in B16 melanoma cells and in human skin explants, thus enhancing pigmentation (Madi et al., 2013) .
Increasing evidence highlights a crucial involvement of protein kinase A and Akt in the inactivation of glycogen synthase kinase 3b, a key element in the Wnt signaling pathway, generally active during embryogenesis and tumorigenesis to increase cell cycle progression and cell proliferation. This effect has been induced by IB-MECA in melanoma, in hepatocellular carcinoma, in synoviocytes from rheumatoid arthritis (RA) patients, and in adjuvant-induced arthritis rats (Fishman et al., 2002a; Bar-Yehuda et al., 2008; Ochaion et al., 2008) .
The number of pathways seen to be triggered by A 3 AR makes an in-depth understanding of the complexity of such signaling in different cellular elements and pathologies of paramount importance (Fig. 3) .
VII. Biologic Functions and Therapeutic Applications of the A 3 Adenosine Receptor

A. Central Nervous System
There is interest in understanding A 3 AR involvement in normal and pathologic conditions of the CNS despite its low expression in the brain (Rivkees et al., 2000; Burnstock et al., 2011) . The role of A 3 ARs in several diseases is often controversial, depending on acute and chronic agonist administration (Jacobson, 1998; Von Lubitz, 1999) . It has been hypothesized that A 3 ARs play a protective role in the first phase of The A 3 Receptor: History and Perspectives ischemia by decreasing synaptic transmission (Pugliese et al., 2003; Rivera-Oliver and Diaz-Rios, 2014 ). However, with prolonged A 3 AR stimulation the effects transform from protective to injurious, increasing excitotoxicity (Pugliese et al., 2007) .
A proconvulsant effect of A 3 ARs has been observed in the immature brain, suggesting that it may facilitate seizure-induced neuronal damage (Boison, 2008) . Accordingly, it has also been reported that A 3 ARs decrease the stability of currents generated by gamma aminobutyric acid in different epileptic tissues, thus suggesting that adenosine antagonists may offer therapeutic opportunities in various forms of human epilepsy (Roseti et al., 2009) .
A 3 AR agonists have been reported to depress locomotor activity, thus suggesting a possible inhibition of excitatory neurotransmission in cortical neurons (Boison, 2007) . Similarly, an increased motor activity has been revealed in A 3 AR knockout (KO) mice (Björklund et al., 2008a) . It was recently demonstrated that A 3 AR receptors are present in the nerve terminal and muscle cells at the neuromuscular junctions. The presence of these receptors in the neuromuscular synapse allows the receptors to be involved in the modulation of transmitter release (Garcia et al., 2014) .
A 3 AR is able to reduce excitotoxicity and promote neuroprotection in hippocampal CA3 pyramidal neurons, after ischemic damage, through coactivation of mGluR1; the mechanism involved is endocytosis and subsequent degradation of AMPAR protein levels (Dennis et al., 2011; Sebastiao et al., 2012) . Neuroprotection has also been observed through inhibition of P2X7 receptorinduced death of rat retinal ganglion cells .
An upregulation of A 3 ARs has been reported in the hippocampus of a transgenic mouse model of Alzheimer's disease where altered oxidative phosphorylation was detected before amyloid deposition, whereas no change has been observed in the brains of Parkinson's patients (von Arnim et al., 2006; Varani et al., 2010b) . Interestingly investigations have shown that A 3 AR stimulation rapidly enhances the activity of antidepressant-sensitive serotonin transporters and that the stimulation of SERT activity is lost in A 3 AR KO mice (Zhu et al., 2011) . A 3 ARstimulated SERT activity is primarily mediated by p38 MAPK-linked pathways, thus supporting the idea that the use of agents that selectively block A 3 ARs may diminish SERT surface expression and activation. This evidence suggests the use of A 3 AR antagonists for the treatment of mood disorders characterized by hyposerotonergic states (Zhu et al., 2007 (Zhu et al., , 2011 .
Glial A 3 AR activation by high adenosine levels subsequent to brain injury may be implicated in neuroinflammatory tissue responses (Hammarberg et al., 2003 (Hammarberg et al., , 2004 . A role for A 3 AR as dynamically regulated suppressors of A 2A -mediated inhibition of proinflammatory cytokine responses was reported in microglial cells where A 3 AR signaling may also be involved in the ADP-induced process extension and migration (van der Putten et al., 2009; Ohsawa et al., 2012) . In contrast, an anti-inflammatory effect, leading to a reduction in LPS-stimulated TNF-a production and cell migration, was observed in the same cells (Lee et al., 2006a; Choi et al., 2011) .
A 3 AR stimulation of neuroprotective substances was also shown in mouse astrocytes (Wittendorp et al., 2004) . As regards neuroprotection, A 3 ARs inhibit LPSinduced HIF-1a accumulation in murine astrocytes, thus resulting in downregulation of the genes involved in inflammation and hypoxic injury, i.e., inducible nitric oxide synthase and A 2B ARs receptors, in both normoxic and hypoxic conditions, thus adding a novel mechanism responsible for protective effects against brain injury .
To date, several A 3 AR neuroprotective and antiinflammatory effects have been demonstrated although further studies are needed before clinical utility can be achieved.
B. Cardiovascular System
Several studies in neonatal rat cardiomyocytes suggest that A 3 AR stimulation produces direct cardioprotective effects (Germack and Dickenson, 2005; McIntosh and Lasley, 2012) . Although there is low A 3 AR expression in myocardial tissue, a number of works demonstrated that acute treatment with agonists induces protective "antiischemic" effects (Auchampach et al., 1997; Tracey et al., 1997; Thourani et al., 1999a,b; Ge et al., 2006 Ge et al., , 2010 Xu et al., 2006; Chanyshev et al., 2012) . These findings have also been confirmed in A 3 AR-overexpressing mice, where infarct size was smaller than in wild-type mice after in vivo regional IR (Shneyvays et al., 2004) . Similarly, antiischemic effects have been found with positive allosteric modulators as well as with dendrimeric A 3 AR agonists (Wan et al., 2011; Du et al., 2012; Chanyshev et al., 2012) .
As for the timing of cardioprotection, there is significant evidence that A 3 AR activation exerts a cardioprotective effect both before ischemia and during reperfusion (Gessi et al., 2008b; McIntosh and Lasley, 2012) . Interestingly, some studies have indicated that protection occurs postischemia through inhibition of either neutrophil-induced reperfusion injury or myocyte apoptotic cell death (Jordan et al., 1999; Maddock et al., 2002) ; others, instead, have found that preischemic A 3 AR activation is effective and necessary for cardioprotection (Thourani et al., 1999a,b) . It has been demonstrated that A 3 AR agonism is able to trigger an anti-infarct response with either pre-or postischemic treatment (Auchampach et al., 2003) . Moreover, A 3 AR activation is able to mimic or induce myocardial preconditioning, meaning that transient stimulation of the A 3 AR before induction of ischemia leads both to early and to delayed protection (Peart and Headrick, 86 2007) . Preconditioning through AR modulation may have clinical relevance (for example, in cardiac surgery) although pretreatment is rarely permitted in acute myocardial infarction. For this reason, achieving protection from IR injury through administration of the drug after ischemia or during reperfusion would be more useful (Nishat et al., 2012) .
A novel prosurvival pathway by which A 3 ARs ameliorate myocardial ischemia/reperfusion injury is through its effect on caspase-3 activity, MEK1/2-ERK1/2, and PI3K/AKT (Hussain et al., 2014) . There is also evidence that A 3 ARs enhance cellular antioxidant capacity, thus contributing to vasoprotection and reduced cardiac myocyte death and strongly supporting an A 3 ARdependent cardioprotective response. These effects have reduced infarct size, inhibited apoptosis, and improved postischemic contractile function (Zhai et al., 2011) . According to powerful cardioprotective effects against myocardial injury, A 3 AR activation has also been found to improve myocardial survival against cardiotoxic sideeffects induced by chemotherapy (Sandhu et al., 2014) .
A 3 AR has, moreover, been seen to play a role in the modulation of blood vessel function (Burnstock and Ralevic, 2014) . Activation of A 3 AR leads to endotheliumdependent aortic contraction through cyclooxygenase-1, which may play a role in cardiovascular inflammation, including hypertension and atherosclerosis (Ansari et al., 2007) . A 3 AR has also been shown to 1) inhibit or negatively modulate coronary flow in isolated mouse heart (Talukder et al., 2002) , 2) cause vasoconstriction in hamster arterioles (Shepherd et al., 1996) , and 3) reverse vascular hyporeactivity after hemorrhagic shock in rats (Zhou et al., 2010) . A 3 AR-mediated vasoconstriction may involve indirect signaling through nonvascular cell types, such as mast cells that may reside within the vascular wall, by releasing such factors as histamine and thromboxane Zhao and Kukreja, 2002) . Indeed, A 3 AR-mediated vasoconstriction has been proved to depend on the inhibition of cAMP accumulation in smooth muscle and in cultured aorta (Talukder et al., 2002) . Another pathway linking A 3 AR to contraction of the mouse aorta is through ROS generation, via activation of NADPH oxidase 2 (ElAwady et al., 2011). It has recently been reported that, via A 2B and A 2A /A 3 ARs, adenosine induces hyaluronan matrix modulation in the smooth muscle cells of the human coronary artery, thereby increasing smooth muscle cells proliferation, migration, and monocyte adhesion. For this reason, adenosine has been proposed as a regulator of plaque stability and inflammatory cell trafficking in atherosclerosis (Reiss and Cronstein, 2012; Grandoch et al., 2013) . However, although a genetic deficiency in the A 3 AR subtype has been demonstrated as significantly reducing the proliferative potential of aortas in organ culture, it does not attenuate the development of atherosclerotic lesions in response to a high-fat diet or vascular injury in vivo (Jones et al., 2004) . On the other hand, it has been shown that, in hypoxic foam cells, adenosine stimulates HIF-1a accumulation, vascular endothelial growth factor secretion, and foam cell formation, suggesting the potential use of A 3 AR antagonists in blocking major steps in atherosclerotic plaque development (Gessi et al., 2010a) .
In conclusion, in the cardiovascular system, A 3 AR modulation appears to have an important protective function. However, this area needs greater exploration through clinical studies to confirm the evidence for preclinical models.
C. Pulmonary System
The role of adenosine in regulating the respiratory system is well known and elevated levels of the nucleoside have been found in bronchoalveolar lavage, blood, and exhaled breath condensate of patients with asthma and chronic obstructive pulmonary disease (COPD).
It is known that A 3 ARs may be involved in both proor anti-inflammatory responses depending on the cell type involved . In particular, the strongest evidence for a functional role of A 3 AR in mast cell activation comes from the use of genetic A 3 AR and mast cell KO mice where degranulation appears to depend on A 3 AR activation, thus suggesting that adenosine exposure can result in A 3 AR-dependent airway inflammation . Likewise, adenosine fails to induce histamine release from lung mast cells obtained from A 3 AR KO mice and mediated airway hyperresponsiveness by both A 3 AR-dependent and -independent mechanisms in rodents (Zhong et al., 2003) . Accordingly, in A 3 AR KO mice the reconstitution of wild-type mast cells restores the airway hyperresponsiveness (Hua et al., 2008) . In contrast, in a bleomycin model of pulmonary inflammation and fibrosis, A 3 ARs have provided anti-inflammatory functions, regulating production of the mediators involved in fibrosis (Morschl et al., 2008; Burnstock et al., 2012) . Although A 3 AR protein has not been found in human lung mast cells, it is highly present in human eosinophils with antiinflammatory functions (Reeves et al., 2000; Hasko et al., 2008) . As A 3 ARs inhibit degranulation of eosinophils, it has been speculated that specific A 3 AR agonists might be useful in eosinophil-dependent allergic disorders, such as asthma and rhinitis (Spicuzza et al., 2006) . However, adenosine deaminase KO mice treated with selective A 3 AR antagonists have shown a marked attenuation of pulmonary inflammation, decreased eosinophil infiltration, and reduced airway mucus production (Young et al., 2004) .
Interestingly, COPD patients have shown decreased A 2B AR density and increases in A 2A and A 3 ARs in peripheral lung compared with the levels found in smokers with normal lung function ). An increase in A 3 ARs found in bronchoalveolar The A 3 Receptor: History and Perspectives 87 lavage macrophages from COPD patients appears to be closely associated with the presence of high levels of proinflammatory cytokines. In a human leukemic monocyte lymphoma cell line (U937), IL-1b, and TNF-a are both able to bring about significant increases in A 2A and A 3 AR density (Varani et al., 2010) . In contrast, A 3 AR agonists have been suggested as a potential effective therapy for IR-induced lung injury (Matot et al., 2006) . Indeed, inosine has been seen to have antiinflammatory effects in allergic lung inflammation by recruiting A 3 ARs (da Rocha Lapa et al., 2013) . Accordingly, A 3 AR activation was recently found to attenuate lung IR injury through a neutrophil-dependent mechanism, suggesting the use of A 3 AR agonists as a novel therapeutic strategy to prevent lung IR injury and primary graft dysfunction after transplantation (Gazoni et al., 2010; Mulloy et al., 2013) .
The role of A 3 AR in the human lung has still to be clarified, although data in recent literature would appear to lean toward a protective effect.
D. Immune System and Inflammation
A 3 ARs are present in immune cells and are involved in the physiopathologic regulation of inflammatory and immune processes mediated by adenosine (Antonioli et al., 2010; Hasko and Cronstein, 2013) .
Neutrophil behavior is strongly affected by the A 3 AR mediating inhibition of the oxidative burst and chemotaxis with anti-inflammatory activity (Bouma et al., 1997; Gessi et al., 2002; van der Hoeven et al., 2008) . Accordingly, these effects have also been observed in a model of severe IR injury after lung transplantation (Mulloy et al., 2013) . On the other hand, it was also reported that, together with P2Y2, A 3 AR guides neutrophil chemotaxis after ATP release (Chen et al., 2006) and also plays a role in neutrophil migration by positively affecting innate immune response (Butler et al., 2012) . In particular, this adenosine subtype aggregates in immunomodulatory microdomains on human neutrophil membranes and promotes the formation of bacteria-tethering cytonemes, which are important for phagocytosis, thus suggesting a key role in innate immune response (Corriden et al., 2013) .
Adenosine has been proposed as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumors (Hoskin et al., 1994a (Hoskin et al., ,b, 2002 . The nucleoside interferes with activation-induced expression of the costimulatory molecules CD2 and CD28, possibly through A 3 AR recruitment (Butler et al., 2003) . However, the adenosine-mediated inhibitory effect on the ability of lymphokine-activated killer cells to kill tumor cells has essentially been attributed to the cAMPelevating A 2A AR (Raskovalova et al., 2005) . In contrast to the immunosuppressive role of adenosine in the environment of solid tumors, A 3 AR stimulates murine bone marrow cell proliferation in vitro through the production of the granulocyte colony-stimulating factor by human peripheral blood mononuclear cells (PBMC). Accordingly, when administered before chemotherapy, adenosine increases leukocyte and neutrophil numbers (Fishman et al., 2000) . In addition, A 3 AR activation has been found to enhance natural killer (NK) cell activity and most likely the NK cell-mediated destruction of tumor cells (Harish et al., 2003) . Therefore, it is well established that, within the solid tumor microenvironment, adenosine is an important inhibitor of tumor cell destruction by NK and lymphokineactivated killer cell signaling, primarily through the A 2A and A 3 ARs on the surface of T cells (Hoskin et al., 2008) . Indeed, ex vivo activation of CD8 + T cells with the A 3 AR agonist improves adoptive immunotherapy for melanoma (Montinaro et al., 2012) . We emphasize that the identification of signal transduction pathways, through which adenosine exerts its inhibitory effects on cell-mediated antitumor immune responses, may allow for the development of focused pharmacologic strategies to reduce, or ablate, the impact of adenosinemediated immune suppression in cancer patients (Kumar, 2013) .
Adenosine is an endogenous regulator of monocytemacrophage functions, first producing high amounts of inflammatory mediators during the early stages of inflammation and later participating in the resolution of this process. As for the role A 3 ARs play in the inhibition of macrophage production of TNF-a, discrepant results have been obtained. For example, some studies attributed reduction of TNF-a to A 3 AR in both human and mouse species (Sajjadi et al., 1996; McWhinney et al., 1996; Lee et al., 2006a) , whereas others, using ARs KO mice, found this effect to be mediated essentially by A 2A AR and, to a lesser extent by A 2B AR, without A 3 AR involvement . Still others found that Cl-IB-MECA is able to enhance TNF-a production in LPS-treated macrophages in an NF-kB-dependent manner (Forte et al., 2011) . Further macrophage functions regulated by A 3 AR include the reduction of the chemokine macrophage inflammatory protein (MIP) 1a and the inhibition of interferon regulatory factor 1, inducible nitric oxide synthase, and CD36 gene expression in RAW264.7 murine and THP-1 human cells (Hasko et al., 1996; Barnholt et al., 2009 ). In addition, IB-MECA inhibits the respiratory burst of human monocytes by blocking NADPH oxidase activity (Broussas et al., 1999; Thiele et al., 2004) . In addition to inflammatory mediator modulation, A 3 AR may be involved in human ventricular remodeling by stimulating MMP-9 production, relevant for revascularization, supporting the use of A 3 AR agonists during the remodeling phase (Velot et al., 2008) . Although most studies indicate a role for A 3 AR agonists as inhibitors of inflammation, a recent novel application of A 3 AR antagonists was discovered for a novel series of truncated nucleosides, i.e., that of inhibiting TGF-b1-induced collagen I upregulation, making them appear as good therapeutic 88 candidates for treating renal fibrosis (Nayak et al., 2014) .
Dendritic cells are antigen-presenting cells that are specialized to activate naive T lymphocytes and initiate primary immune responses . The role of A 3 ARs in regulating mature dendritic cell function is less well established (Koscso et al., 2011) . It has been reported that A 1 and A 3 ARs are predominantly expressed in immature human dendritic cells and that their stimulation induces Ca 2+ mobilization from intracellular stores, actin polymerization, and chemotaxis (Panther et al., 2001) . Mature dendritic cells, however, downregulate A 3 ARs and mainly present A 2A ARs, and both these subtypes inhibit TNF-a release in the mouse dendritic cell line XS-106 (Dickenson et al., 2003) .
A 3 AR activation affects numerous mast cell functions in rodents and humans including degranulation, apoptosis, and regulation of vasopermeability (Gao et al., 2001; Feoktistov et al., 2003) . Studies performed on cellular and animal models have shown that A 3 AR increases degranulation in rodents (Ramkumar et al., 1993; Reeves et al., 1997; Salvatore et al., 2000; Smith et al., 2002; Zhong et al., 2003) . Although in the past there was no evidence that the A 3 AR played a similar role in human mast cells, recently this effect was reported in human LAD2 mast cells (Feoktistov and Biaggioni, 1995; Ryzhov et al., 2004; Leung et al., 2014) . A 3 ARs are also emerging in the treatment of bowel inflammation, because IB-MECA markedly reduces colon levels of such proinflammatory cytokines as IL-1, IL-6, and IL-12 and decreases local production of MIP1a or MIP-2, thus providing a powerful leukocyte downregulation in bowel inflammation (Mabley et al., 2003) . Different studies have evaluated the effects of A 3 AR agonists on gene dysregulation and tissue injury in rat models of colitis. A 3 AR agonists prevent the induction of various cytokine/chemokine/inflammatory genes and promote marked suppression of ROS production, which leads to significant amelioration of intestinal injury. In the stomach, jejunum, colon ileum, cecum, and liver, A 3 AR upregulation has been observed during colitis to provide anti-inflammatory processes in the intestine and liver (Mabley et al., 2003; Lee et al., 2006b ). Inhibition of IL-2, TNF-a, and IFN-g production and upregulation of IL-10 have been observed in cultured splenocytes derived from CF101-treated animals, thus pointing toward a marked anti-inflammatory effect .
More recently, A 3 ARs were found to be overexpressed in different autoimmune disorders such as Crohn's disease and psoriasis. The upregulation observed in these pathologies could be attributed to adenosine, which, under conditions of stress, accumulates in the extracellular environment. Most transcription factors, such as NF-kB and CREB, have been revealed as promoting inflammation and being inversely associated with A 3 AR upregulation . Accordingly, CF101 was tested in a phase II, multicenter, randomized, double-blind, dose-ranging, placebo-controlled trial in patients with moderate to severe chronic plaque-type psoriasis. In this study the drug was found to be safe and well tolerated, and the improvement was progressive and linear throughout the period examined (David et al., 2012) . As a consequence, CF101 has entered a phase II/III randomized, doubleblind, placebo-controlled, dose-finding study of the efficacy and safety of daily CF101 administered orally in patients with moderate to severe plaque psoriasis (ClinicalTrials.gov).
Overall, the data in the literature suggest that A 3 AR activation can induce important anti-inflammatory effects in several cellular models. The results achieved thus far with A 3 AR agonists in clinical studies on such major inflammatory conditions as arthritis and psoriasis are quite promising, and we are confident that they will be translated into treatments for other flogosisrelated pathologies.
E. Rheumatoid Arthritis and Ostheoarthritis
Rheumatoid Arthritis is a chronic autoimmune inflammatory disorder of unknown etiology that affects approximately 1% of the population worldwide . It is widely accepted that, to prevent unfavorable outcome, RA must be treated early with effective therapy (Flogel et al., 2012) . Although, in recent years, great progress has been made in this direction, particularly using biologic drugs, to date no univocal, effective, and safe pharmacologic treatment is available.
Knowledge of the effects of adenosine has revealed that ARs could be a useful target for RA therapy. Adenosine production has emerged as an important cell mechanism to regulate inflammation due to an increase in receptor density and/or functionality. A 3 ARs are upregulated in RA, psoriasis, and Crohn's disease ). Interestingly they are also overexpressed in untreated RA patients and in methotrexatetreated RA patients, and administration of anti-TNF-a drugs normalizes their number and functionality ). Furthermore, A 3 AR density inversely correlates with Disease Activity Score in 28 or 44 joints, suggesting a direct role of the endogenous activation of these receptors in the control of RA inflammation (Varani et al., 2011b) . The overexpression of A 3 ARs in RA has been directly linked to the increase in NF-kB, a key player in the pathogenesis of arthritic diseases Ochaion et al., 2009) .
In RA patients, adenosine suppresses the elevated levels of proinflammatory cytokines such as TNF-a and IL-1b, and clinical evidence has shown that A 3 AR agonists modulate an improvement in signs and symptoms of the disease (Forrest et al., 2005; Silverman et al., 2008) . Furthermore, A 3 AR agonists prevent The A 3 Receptor: History and Perspectives cartilage damage, osteoclast/osteophyte formation, bone destruction, and markedly reduce pannus and lymphocyte formation in rat models Bar-Yehuda et al., 2009 ). The anti-inflammatory effect of A 3 ARs has also been observed in fibroblastlike synoviocytes derived from the synovial fluid of RA patients and is closely associated with a decrease in NF-kB and TNF-a release . Oral treatment with CF101 has led to amelioration and a marked decrease in clinical manifestations of the disease. In a phase I study in healthy subjects, CF101 proved safe and well tolerated, offering linear pharmacokinetic activity (van Troostenburg et al., 2004) . This was confirmed in a now successfully concluded phase II study in RA patients in which CF101 mediated improvement in signs and symptoms, thus suggesting an opportunity for its development as an antirheumatic agent (Silverman et al., 2008; ClinicalTrials.gov) .
The most common form of arthritis is osteoarthritis (OA), which is the most important cause of disability in older adults. The current recommended treatment of OA involves weight loss, physical therapy, and the use of pain relievers. However, these drugs do not reverse the degenerative process in OA and show some adverse effects on cartilage metabolism (Zhang et al., 2008) . It is well known that p38 MAPKs are involved in controlling such cellular responses as adenosine-mediated proinflammatory cytokine release (Fotheringham et al., 2004) . Accordingly, a pathway involving the reduction in p38 MAPKs, NF-kB, TNF-a, and IL-8 by A 3 AR activation was observed in human synoviocytes (Varani et al., 2010c) . It was also reported that the NF-kB signaling pathway is deregulated by the presence of IB-MECA and is involved in OA pathogenesis. In addition, CF101 induces inflammatory cell apoptosis and acts as a cartilage protective agent, suggesting that it may be a suitable candidate for the treatment of OA . The safety and efficacy of CF101 has also been evaluated in a phase II clinical study with patients suffering from OA of the knee (Fishman et al., 2012) .
Interestingly, a link has been found between ARs and their modulation by such physical agents as pulsed electromagnetic fields (PEMFs). In vitro studies on joint cells have suggested that exposure to PEMFs mediates a significant protection against the catabolic effect of proinflammatory cytokines and an anabolic action increasing matrix synthesis and cell proliferation . Moreover, PEMFs are able to mediate the upregulation of A 3 ARs in bovine chondrocytes and synoviocytes (Varani et al., 2008; De Mattei et al., 2009) . These data have been further confirmed in human synoviocytes where the copresence of A 3 ARs and PEMFs reduces the release of PGE2, IL-6, and IL-8, whereas it increases IL-10 release (Ongaro et al., 2012) . Recently, in human T/C-28a2 chondrocytes and human FOB 1.19 osteoblasts, PEMFs and A 3 AR stimulation have been seen to reduce PGE2, IL-6, and IL-8 production, suggesting their potential in the treatment of inflammatory bone and joint disorders . Therefore, PEMFs could be an innovative physiologic alternative to the use of agonists as they can meditate the tissue-specific agonist effects without any desensitization and downregulation. All the above indicates that PEMFs could be a very interesting example of "soft pharmacology."
Overall, in joint diseases, the behavior of A 3 AR strongly suggests that it could play a therapeutic role in this area and underlines the need for further pharmacologic investigation into how the inflammatory conditions closely associated with these diseases are modulated.
F. Muscle System
It is a well reported fact that IR can cause significant injury in skeletal muscle, because this is the most vulnerable tissue in the extremities (Blaisdell, 2002) . Therefore protecting skeletal muscle from IR insult is an important aim of therapy to ameliorate muscle and organ injury (Tsuchida et al., 2003) .
A 3 ARs have been found to protect the skeletal muscle against IR damage. Interestingly, the A 3 AR agonist is a prime candidate for pharmacologic intervention in the first few hours postinjury based on several working hypotheses concerning its mechanism of protection. The pathway involves PLC b2/b3, which in turn activates PKC via diacylglycerol (Zheng et al., 2007) . PKC has been shown to activate K ATP channels and cause protection. That adenosine and ischemic preconditioning of the skeletal muscle have an energysparing effect is consistent with a consequence of sarcolemmal K ATP channel activation. The latter can cause an abbreviation of the muscle action potential duration, reduce Ca 2+ influx and overload, and thus ameliorate ischemic injury (Liang et al., 2010) . Furthermore, the role of the A 3 AR agonist in mitigating Ca 2+ influx and overload, through its effect on PKC signaling, can potentially decrease MMP activation and subsequent upregulation of downstream proteolytic cascades (Liang et al., 2010) .
Another mechanism of A 3 AR protection is its antiinflammatory effect, exerted not at the skeletal muscle level but at the immune cell level. In this signaling pathway, A 3 AR activation on circulating immune cells suppresses their function and decreases immune cellmediated damage to the skeletal muscle. This concept is supported by the finding that activated mast cells and neutrophils are important contributors to, if not mediators of, skeletal muscle IR damage (Fishman et al., 2012) .
G. Eye Diseases
A 3 ARs have been widely implicated in many ocular diseases including dry eyes, glaucoma, and uveitis. When compared with normal eyes, A 3 AR mRNA and protein 90 levels are found to be consistently increased in the nonpigmented ciliary epithelium in pseudoexfoliation syndrome with glaucoma (Schlotzer-Schrehardt et al., 2005) .
In the past, A 3 AR KO mice showed lower intracellular pressure, thus suggesting that A 3 AR antagonists could play a role in the treatment of glaucoma (Yang et al., 2005) . In addition, the use of A 3 AR antagonists appears to be a specific, alternate approach for treating ocular hypertension in patients affected by the pseudoexfoliation syndrome in open angle glaucoma, which is typically associated with anterior chamber hypoxia and elevated intraocular pressure (IOP) (Yang et al., 2005) . Accordingly, a series of nucleoside-derived antagonists have been found to lower IOP across species (Wang et al., 2010) . Recently, it was reported that adenosine may trigger oligodendrocyte death via activation of A 3 AR, suggesting that this mechanism contributes to optic nerve and white matter ischemic damage (González-Fernández et al., 2014) .
On the other hand, it was shown that, in retinal ganglion cells, A 3 AR prevents activation of the P2X 7 / NMDA receptors responsible for the rise in Ca 2+ and apoptosis, thus suggesting the neuroprotective potential of A 3 AR agonists in glaucoma treatment. These findings were confirmed in in vivo experiments (Zhang et al., 2006b Hu et al., 2010) . CF101 entered a clinical phase of drug development. Studies from a phase II clinical trial revealed that it was well tolerated and induced a statistically significant improvement in patients with moderate to severe dry eye syndrome. Interestingly, in the same clinical trial, CF101 decreased IOP, thus demonstrating its efficacy as an IOP-lowering agent. These data, and the anti-inflammatory characteristics of CF-101, support pursuing study of this drug as a potential treatment of the signs and symptoms of dry eye syndrome and glaucoma (Avni et al., 2010; Fishman et al., 2013) . Indeed now CF101 has entered a phase II, randomized, double-masked, placebo-controlled, parallelgroup study of the safety and efficacy of daily CF101 administered orally in subjects with elevated intraocular pressure (ClinicalTrials.gov).
CF101 has also been effective in an experimental model of autoimmune uveitis, supporting further exploration of this molecule for the treatment of uveitis . Oral treatment with CF101, initiated upon disease onset, improves clinical uveitis fundoscopy score and ameliorates the pathologic manifestations of the disease. Now CF101 has entered a phase II, randomized, double-masked, placebo-controlled study of the safety and efficacy of daily CF101 administered orally in subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis (ClinicalTrials.gov).
H. Cancer
A very interesting area of possible application for A 3 AR ligands is in cancer therapy. The possibility that A 3 AR may play a role in the development of cancer was suggested several years ago (Fishman et al., 1998 (Fishman et al., , 2000 Merighi et al., 2003; Gessi et al., 2011b) .
Adenosine is present at high levels in cancer tissues and in the interstitial fluid of several tumors, in sufficient concentration to interact with ARs (Blay et al., 1997; Antonioli et al., 2013) . In particular, A 3 ARs are present in different types of tumor cells, such as HL60 and K562 human leukemia , Jurkat , and U937 human lymphoma (Gessi et al., 2010a) , Nb2 rat lymphoma (Fishman et al., 2000) , A375 human melanoma , PGT-beta mouse tumor pineal gland (Suh et al., 2001) , human glioblastoma (Merighi et al., 2006; Gessi et al., 2010b) , human prostatic (Jajoo et al., 2009) , and mesothelioma cells . A 3 AR subtype overexpression has also been demonstrated in colon cancer tissues, compared with normal mucosa, obtained from patients undergoing surgery (Gessi et al., 2004a; Madi et al., 2004) . Upregulation in tissues is reflected in peripheral blood cells, thus making this adenosine subtype a possible marker for cancer (Gessi et al., 2004a) . Another study showed upregulated A 3 AR mRNA expression in hepatocellular carcinoma (HCC) tissues compared with adjacent normal tissues (BarYehuda et al., 2008) . Remarkably, upregulation of A 3 AR was noted in PBMCs derived from HCC patients compared with healthy subjects. Interestingly, these results suggest that, in PBMCs, A 3 AR reflects receptor status in remote tumor tissue (Gessi et al., 2004a) . Similarly, in malignant mesothelioma pleura, mRNA, and protein expression of A 3 ARs have been found statistically increased with respect to healthy mesothelial pleura .
Clinical investigations have clearly shown that the prevalence of hypoxic tissue areas is a specific property of solid tumors (Melillo et al., 2004) . Furthermore, hypoxia appears to induce increased intracellular adenosine levels and stabilize the most important factors involved in hypoxia, such as HIF-1a. A 3 ARs stimulation induces HIF-1a accumulation in different cancer cell lines (Merighi et al., 2005a (Merighi et al., , 2006 . This has been seen to lead to an increase in angiopoietin-2 and/or vascular endothelial growth factor, depending on the cell model investigated (Merighi et al., 2007b) .
As for the role the A 3 AR subtype plays in cancer cells, several other functions have been described. Both pro-and antiapoptotic as well as pro-and antiproliferative effects have been reported depending on the level of receptor activation (Jacobson, 1998; Merighi et al., 2005b; Gessi et al., 2007; Kim et al., 2010; Taliani et al., 2010; Varani et al., 2011a; Sakowicz-Burkiewicz et al., 2013) . At first, telomerase activity inhibition and cytostatic effects were observed in tumor cells (Fishman et al., 2000 (Fishman et al., , 2001 . Then the intracellular pathway involved in A 3 AR-mediated tumor growth inhibition was identified (Fishman et al., , 2012 . In contrast, The A 3 Receptor: History and Perspectives some studies showed that A 3 AR agonist inhibition of cell proliferation was only obtained by micromolar concentrations (Lu et al., 2003; Merighi et al., 2005b; Nakamura et al., 2006) . Furthermore, in U87MG cells, A 3 AR stimulation induced an increase in MMP-9, through the AP-1 activation responsible for increased glioblastoma cell invasion, as observed in macrophages (Velot et al., 2008; Gessi et al., 2010b) . However, other studies reported that A 3 ARs reduces the ability of prostate cancer cells to migrate in vitro and metastasize in vivo (Jajoo et al., 2009) . Accordingly, in the same cells, IB-MECA inhibits cell proliferation and induces G1 cell cycle arrest, apoptosis, and migration (Morello et al., 2009; Aghaei et al., 2011) . Stimulation of A 3 ARs exerts a cytotoxic and proapoptotic effect on malignant mesothelioma cells . Interestingly, the antitumor effect of A 3 ARs is potentiated by PEMFs in cultured neural cancer cells such as PC12 and U87MG glioblastoma cells, thus decreasing NF-kB activation and cell proliferation. Moreover, PEMF and A 3 AR stimulation are able to significantly increase p53 levels, cytotoxicity, and apoptosis in tumor cells .
A 3 AR agonists have also been investigated in in vivo studies. In all the experimental models, given their stability and bioavailability profile, the drugs were administered orally. The studies included syngeneic, xenograft, orthotopic, and metastatic experimental animal models utilizing IB-MECA and Cl-IB-MECA in melanoma, colon, prostate, and hepatocellular carcinomas. A 3 AR agonists prevented the growth of primary B16-F10 murine melanoma tumors in syngeneic models. Moreover, in an artificial metastatic model, IB-MECA inhibited the development of B16-F10 murine melanoma lung metastases. Response specificity was demonstrated by A 3 AR antagonist administration which reversed the effect of the agonist. Furthermore, in combination with the chemotherapeutic agent cyclophosphamide, IB-MECA, or Cl-IB-MECA induced an additive antitumor effect on the development of B16-F10 melanoma lung metastatic foci (Fishman et al., 2009 ). In addition, the combination of Cl-IB-MECA and paclitaxel caused significant cytotoxicity on two melanoma cell lines through multiple mechanisms of cell death (Soares et al., 2014) . Furthermore, in xenograft models, IB-MECA counteracted the development of human colon and prostate carcinoma in nude mice. In these studies, the combined treatment with IB-MECA and 5-fluorouracil or taxol, respectively, resulted in an enhanced antitumor effect. IB-MECA prevented the growth of primary and liver metastases of CT-26 colon carcinoma cells inoculated in the spleen. Finally, Cl-IB-MECA treatment dose dependently inhibited hepatocellular tumor growth and reduced liver inflammation (Gao and Jacobson, 2007; Bar-Yehuda et al., 2008; Fishman et al., 2009; Cohen et al., 2011) . Accordingly, Cl-IB-MECA significantly reduced tumor growth and cancer pain in rat bone-residing breast cancer .
The safety and clinical effects of CF102 were assessed in patients with advanced unresectable HCC, in a phase I/II trial. This study included 18 hepatocellular carcinoma patients treated with three different doses of CF102 to determine the pharmacokinetic behavior and safety profile of long-term administration (Stemmer et al., 2013) . Owing to its safety and favorable pharmacokinetic characteristics, phase II trial for advanced liver cancer is ongoing (ClinicalTrials.gov).
Overall, these data suggest that A 3 ARs might be a biologic tumor marker and that A 3 AR modulation could be used to treat cancer.
I. Pain
Chronic neuropathic pain is a major unresolved health care issue with global human and socioeconomic impact (5-10% occurrence in Europe and the United States). Its general incidence is augmented by pain from chemotherapy-induced peripheral neuropathy. Therefore, the identification of novel therapeutic targets that can effectively resolve this condition would be necessary.
The contribution of A 3 AR in pain states has been evaluated in different studies. A nociceptive and proinflammatory response resulting in edema formation was first demonstrated after activation of A 3 AR; this effect was mediated by both serotonin and histamine release, most likely from mast cells and subsequent actions on the sensory nerve terminal (Sawynok et al., 1997) . Then, there was less heat hyperalgesia after carrageenan in A 3 ARKO mice probably due to reduced inflammation (Wu et al., 2002) . Furthermore, investigation of the behavioral effects of A 3 ARKO mice showed a decreased sensitivity to some painful stimuli (Fedorova et al., 2003) . However an opposite activity in pain modulation was observed in further studies. Intrathecal delivery of IB-MECA attenuated the inflammatory component of the formalin test (Yoon et al., 2005) . In addition, recently, the treatment of chronic neuropathic pain was proposed as a novel potential application of A 3 AR agonists (Paoletta et al., 2013) . A 3 AR agonists blocked the development of mechanically and chemotherapyinduced neuropathic pain in a dose-dependent fashion and significantly augmented the analgesic effects of currently used analgesics (Chen et al., 2012) . Accordingly, in an animal model of surgery-induced metastasis Cl-IB-MECA significantly reduced bone cancer pain, providing the pharmacologic rationale for using selective A 3 AR agonists as a new approach in chronic neuropathic pain . Interestingly, very recently, the first mechanistic insight into beneficial effects of A 3 AR agonists against neuropathic pain has been explored (Janes et al., 2014a,b) . In particular it has been found that these effects were due to the inhibition of an astrocyte-associated neuroinflammatory 92 response in a model of oxaliplatin-induced peripheral neuropathy (Janes et al., 2014b) . Furthermore A 3 AR agonists were found to prevent the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways (Janes et al., 2014a) . Importantly, the activation of A 3 AR in humans by potent, selective, and orally bioavailable A 3 AR agonists is not associated with cardiac or hemodynamic side effects at variance with A 1 and A 2A ARs and could represent a viable therapeutic strategy for chronic pain of distinct etiologies. There is evidence for both central and peripheral sites of action of A 3 AR agonists in protection against chronic neuropathic pain, and there is a need for new pharmacologic tools to explore this phenomenon. The biochemical basis underlying the protective and beneficial effects of A 3 AR agonists in chronic neuropathic pain is unknown and deserves further in depth investigation. It has been hypothesized that mitoprotective effects and/or attenuation of neuroinflammatory processes in spinal cord mediate the underlying protective A 3 AR role.
From a translational perspective, this could hopefully lead to a rapid investigation of A 3 AR agonists, already in clinical trials, for neuropathic pain treatment.
VIII. Recent Drug Development Efforts
Allosteric modulation of GPCRs now represents one of the most exciting areas in modern drug discovery. One GPCR system that is of particular interest with respect to allosteric modulation is adenosine and its A 3 AR subtype.
Today our knowledge of the GPCR structure has been substantially improved by providing greater understanding of the conformational changes that occur when an agonist binds to the receptor at the same site as the endogenous ligand, the so-called orthosteric site Rasmussen et al., 2011; Hill et al., 2014) . However, in recent years it has become evident that drugs can also bind to a topographically distinct site (allosteric) on the GPCR protein and induce conformational changes that modify the affinity, or efficacy, of a ligand occupying the classic orthosteric binding site (Kenakin, 2009 (Kenakin, , 2012 Keov et al., 2011) . Key molecular scaffolds that support allosteric modulation at the A 3 AR have been identified, 3-(2-pyridinyl)isoquinolines (e.g., VUF5455) and [
3 H]imidazo-[4,5-c]quinolin-4-amines (e.g., LUF5999, LUF6000, and LUF6001), with differing effects on the affinity and efficacy of a selective A 3 AR agonist (Goblyos et al., 2009; Can-fite Biopharma, 2010; Gao et al., 2011) (Fig. 4) . LUF6000 was shown to enhance agonist efficacy in a functional assay and decrease agonist dissociation rate without affecting agonist potency.
In an attempt to overcome the issues associated with the orthosteric antagonism shown by 3-(2-pyridinyl) isoquinolines, a series of ring opened imidazoquinolinamines were synthesized to afford a range of 2,4-disubstituted quinolines as a new class of A 3 AR allosteric enhancers (Heitman et al., 2009) . Notably, the best compound (LUF6096) was not only able to allosterically enhance the binding of Cl-IB-MECA to a similar level as LUF6000, but also displayed negligible orthosteric affinity for any of the AR subtypes. The ubiquitous distribution of ARs and the potential for serious side effects via the target receptor in a different organ or cell type can limit their utility. Allosteric enhancers may represent a strategy to overcome these limitations. However, although in vitro studies have provided convincing evidence for allosteric mechanisms of action for a number of ligands, therapeutic application of these mechanisms relies on their successful translation into whole animal physiology. The efficacy of LUF6096 in an in vivo model of infarction has been shown to be a good starting point (Du et al., 2012) . Indeed, LUF6096 had no effect on baseline hemodynamic parameters; however, pretreatment with LUF6096 before coronary occlusion and during reperfusion produced a marked reduction in infarct size (Du et al., 2012 ). An equivalent reduction was also demonstrated if LUF6096 was administered immediately before reperfusion (Du et al., 2012) . It would therefore appear that allosteric enhancers of A 3 AR may prove to be highly useful therapeutic strategies, selectively augmenting the actions of adenosine released locally under conditions of disease and stress. However, more in-depth investigation is required into the potential of these molecules to increase selective actions of adenosine in specific organs and cell types in whole animal.
Another original effort to improve A 3 AR activation has been the attachment of methanocarba adenosine derivatives to PAMAM dendrimers (Jacobson and Melman, 2010) (Fig. 4) . Dendrimers are tree-like polymers widely used in in vivo drug delivery that can serve as biocompatible polymeric nanocarriers of bioactive molecules of interest (Menjoge et al., 2010) . These multivalent GPCR ligand-dendrimer conjugates display pharmacologic properties that are qualitatively different from those of monomeric drugs and might be useful as novel tools to study GPCR homo-and heterodimers and higher aggregates. Assuming proper functionalization of a ligand for covalent conjugation, the resulting GPCR ligand-dendrimer conjugates have displayed dramatically increased potency or selectivity in comparison with the monomeric, small molecular ligands (Kim et al., 2008a; Jacobson, 2010) . The use of nanocarriers for stably conjugated drugs that act at the cell surface may provide pharmacokinetic and pharmacodynamic advantages, such as the prevention of premature degradation (Kim et al., 2008a; Jacobson, 2010) . These derivatives have been claimed for the treatment of inflammation, cardiac ischemia, stroke, asthma, diabetes, The A 3 Receptor: History and Perspectives and cardiac arrhythmias (Jacobson and Melman, 2009 ). Interestingly, it has been demonstrated that the PAMAM dendrimer conjugate specifically activates A 3 ARs to improve postischemic/reperfusion function in isolated mouse hearts (Wan et al., 2011) . Similar results were confirmed in rat primary cardiac cell cultures and in the isolated heart where these strategically derivatized nucleosides display enhanced cardioprotective potency (Chanyshev et al., 2012) . In vivo testing will now be needed to explore the effects on pharmacokinetics and tissue targeting. The potential of this approach for use in animal models of disease is still to be proven, and such important points as cellular uptake, pharmacologic effects of ligands binding to adjacent GPCR proteins, changes in selectivity according to conjugate composition, and side effects all need to be addressed (Jacobson, 2010) .
IX. Concluding Remarks
Investigation of A 3 ARs and their ligands is rapidly growing and having an increasing impact on the drug discovery process. There is now extensive evidence that A 3 ARs are involved in the physiologic regulation of several homeostatic processes and in the etiology of many diseases (Fig. 5) . The present review documents the state of knowledge of the adenosine A 3 AR. It covers a wide range of information, including data from studies of theoretical, molecular and cellular pharmacology, signal transduction, new drug discoveries, and clinical applications. Detailed understanding of the physicochemical aspects and molecular biology of the A 3 AR provides a solid basis for its future development as a target for adenosine-based pharmacotherapies. Recognition and characterization of intracellular 94 pathways modulated by A 3 AR activation support the belief that modulating these signaling routes is likely to lead to considerable advances in the management of many diseases. The identification of new, potent, and selective A 3 AR ligands opens new frontiers for the elucidation of the therapeutic potential arising from stimulating or blocking the A 3 AR. The A 3 AR appears to play a prominent role under ischemic conditions and remains a promising target for treating neurodegenerative diseases associated with acute ischemia. In terms of clinical utility, it will be critical to explore in greater detail the efficacy of the A 3 AR-mediated protective response in diseased hearts and skeletal muscle. There is emerging evidence that the A 3 AR may be a good target in neuropathic pain. A 3 ARs are present in all immune cells and are involved in the regulation of inflammatory and immune processes, suggesting new therapeutic strategies may emerge for inflammatory conditions such as sepsis, asthma, and autoimmune disorders including rheumatoid arthritis, Crohn's disease, and psoriasis. The oral bioavailability of certain A 3 AR agonists together with encouraging data from clinical studies support the development of these agents as antirheumatic drugs. The effectiveness of the A 3 AR agonist Cl-IB-MECA in several animal tumor models has led to the introduction of this molecule into a program of clinical studies. The excellent safety profile has brought about the initiation of phase II clinical studies in patients with hepatocellular carcinoma, which are currently ongoing. Based on the important scientific and clinical advances overviewed in this review, it would seem that purine scientists are definitely getting closer to their goal of transforming adenosine ligands into drugs with the ability to save lives and improve human health.
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